Theravance Biopharma (TBPH) Phase 2b Dose-Finding Induction Study of Izencitinib Did Not Meet Primary Endpoint
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Theravance Biopharma (TBPH) PT Lowered to $18 at Needham & Company
August 24, 2021 6:24 AM EDTNeedham & Company analyst Joseph Stringer lowered the price target on Theravance Biopharma (NASDAQ: TBPH) to $18.00 (from $32.00) while maintaining a Buy rating.
The analyst commented, "TBPH announced yesterday the izencitinib Ph2b RHEA trial in Ulcerative Colitis (UC) failed to demonstrate efficacy vs... More
Theravance Biopharma (TBPH) falls 21% as trading resumes after a trial missed the primary endpoint
August 23, 2021 4:37 PM EDTTheravance Biopharma (NASDAQ: TBPH) falls 21% as trading resumes after a trial missed the primary endpoint.
... MoreTheravance Biopharma (TBPH) to resume trading at 4:35PM ET after a trial did not meet the primary endpoint
August 23, 2021 4:10 PM EDTTheravance Biopharma (NASDAQ: TBPH) to resume trading at 4:35PM ET after a trial did not meet the primary endpoint.
... More